nt219
purple biotech
['nt219']
#cedarssinaicancer at #asco22. dr. rodolfo gutierrez is a co-author on interim safety and efficacy results from a phase 1 study of nt219 in adults with advanced solid #tumors. 
Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report.